Cycle Vita™ expands patient support in Multiple Sclerosis (MS) to include BAFIERTAM® (monomethyl fumarate) delayed-release capsules
Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the acquisition of Banner Life Sciences, LLC.
New US product launch, VENXXIVA™ (tiopronin) Delayed-Release Tablets for the treatment of cystinuria
Cycle Pharmaceuticals Limited (Cycle) announced today the launch of VENXXIVA (tiopronin) Delayed-Release Tablets, for the treatment of cystinuria, approved by the US Food and Drug Administration (FDA).1 VENXXIVA is launched in partnership between Cycle and Torrent Pharma Inc. (Torrent), and exclusive distribution partner, Vanscoy Rare Pharmacy (Vanscoy Rare).
New tiopronin delayed-release tablets launch with patient support for the treatment of cystinuria in the US
Cycle Pharmaceuticals Limited (Cycle) is pleased to announce the launch of tiopronin delayed-release tablets as a treatment option for patients with cystinuria.1 Tiopronin delayed-release tablets are available in 100 mg and 300 mg doses, and are approved by the US Food and Drug Administration (FDA).1 Generic tiopronin delayed-release tablets must be taken without food.1
New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment
Cycle Pharmaceuticals Limited (Cycle) is proud to announce the launch of ORMALVI™ (dichlorphenamide) tablets, as a treatment option for patients with hyperkalemic periodic paralysis (HyperPP), hypokalemic periodic paralysis (HypoPP) and related variants, approved by the US Food and Drug Administration (FDA).1
